IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v19y2018i1d10.1007_s10198-016-0865-3.html
   My bibliography  Save this article

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy

Author

Listed:
  • Umberto Restelli

    (University of the Witwatersrand
    Centre for Research on Health Economics, Social and Health Care Management (CREMS)-LIUC-Carlo Cattaneo Univerity)

  • Alfredo Alberti

    (University of Padua)

  • Adriano Lazzarin

    (Università Vita-Salute San Raffaele)

  • Marzia Bonfanti

    (Centre for Research on Health Economics, Social and Health Care Management (CREMS)-LIUC-Carlo Cattaneo Univerity)

  • Carmela Nappi

    (Health Economic and Outcome Research Bristol Myers Squibb S.r.l.)

  • Davide Croce

    (University of the Witwatersrand
    Centre for Research on Health Economics, Social and Health Care Management (CREMS)-LIUC-Carlo Cattaneo Univerity)

Abstract

The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY.

Suggested Citation

  • Umberto Restelli & Alfredo Alberti & Adriano Lazzarin & Marzia Bonfanti & Carmela Nappi & Davide Croce, 2018. "Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affecte," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 37-44, January.
    • Handle: RePEc:spr:eujhec:v:19:y:2018:i:1:d:10.1007_s10198-016-0865-3
    DOI: 10.1007/s10198-016-0865-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-016-0865-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-016-0865-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Francesco Saverio Mennini & Andrea Marcellusi & Massimo Andreoni & Antonio Gasbarrini & Salvatore Salomone & Antonio Craxì, 2014. "Health Policy Model: Long-term Predictive Results Associated With The Management Of HCV-Induced Diseases In Italy," CEIS Research Paper 308, Tor Vergata University, CEIS, revised 17 Feb 2014.
    2. Phil McEwan & Thomas Ward & Hayley Bennett & Anupama Kalsekar & Samantha Webster & Michael Brenner & Yong Yuan, 2015. "Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 10(1), pages 1-16, January.
    3. Phil McEwan & Ray Kim & Yong Yuan, 2013. "Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 53-63, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hayley Bennett & Jason Gordon & Beverley Jones & Thomas Ward & Samantha Webster & Anupama Kalsekar & Yong Yuan & Michael Brenner & Phil McEwan, 2017. "Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 1001-1011, November.
    2. Do Young Kim & Kwang-Hyub Han & Byungyool Jun & Tae Hyun Kim & Sohee Park & Thomas Ward & Samantha Webster & Phil McEwan, 2017. "Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea," PLOS ONE, Public Library of Science, vol. 12(1), pages 1-16, January.
    3. Constanza L Vargas & Manuel A Espinoza & Andrés Giglio & Alejandro Soza, 2015. "Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile," PLOS ONE, Public Library of Science, vol. 10(11), pages 1-16, November.
    4. Yun Lu & Xiuze Jin & Cheng-a-xin Duan & Feng Chang, 2018. "Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China," PLOS ONE, Public Library of Science, vol. 13(4), pages 1-12, April.
    5. Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
    6. Phil McEwan & Thomas Ward & Hayley Bennett & Anupama Kalsekar & Samantha Webster & Michael Brenner & Yong Yuan, 2015. "Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 10(1), pages 1-16, January.
    7. Elisabetta Garagiola & Emanuela Foglia & Lucrezia Ferrario & Paola Meraviglia & Alessandro Tebini & Barbara Menzaghi & Chiara Atzori & Giuliano Rizzardini & Teresa Bini & Antonella D’Arminio Monforte , 2020. "Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice," Health Economics Review, Springer, vol. 10(1), pages 1-11, December.
    8. Bassem Asker & Raghad Jawad & Rabah Asreah & Haydar Jamal & Ahmed Jassem & Muslim Abdelkareem Inaya & Hiwa Abou Baker & Sam Kozma & Eid Mansour & Bryony McNamara & Ryan Miller & Oliver Darlington & Ph, 2021. "Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment," PharmacoEconomics, Springer, vol. 39(11), pages 1327-1341, November.
    9. Andrea Marcellusi & Raffaella Viti & Francesco Damele & Calogero Cammà & Gloria Taliani & Francesco Saverio Mennini, 2016. "Early treatment in HCV: is it a cost-effective option from the Italian perspective?," CEIS Research Paper 370, Tor Vergata University, CEIS, revised 23 Mar 2016.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:19:y:2018:i:1:d:10.1007_s10198-016-0865-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.